The efficacy of TRAIL/ES liposomes was previously evaluated by their ability to neutralize CTCs in the bloodstream [51], to prevent the spontaneous formation of metastatic tumors in an orthotopic xenograft model of prostate cancer [52], and to reduce metastasis following tumor resection in an aggressive triple-negative breast cancer (TNBC) mouse model [53]. This evidence concerns the gene TNFSF10 and Familial prostate cancer.